These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 16002846)

  • 1. Role of genomic markers in colorectal cancer treatment.
    Allen WL; Johnston PG
    J Clin Oncol; 2005 Jul; 23(20):4545-52. PubMed ID: 16002846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer.
    Allen WL; Johnston PG
    Pharmacogenomics; 2005 Sep; 6(6):603-14. PubMed ID: 16143000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting the outcome of chemotherapy for colorectal cancer.
    Allen WL; Coyle VM; Johnston PG
    Curr Opin Pharmacol; 2006 Aug; 6(4):332-6. PubMed ID: 16750422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?
    Koopman M; Venderbosch S; Nagtegaal ID; van Krieken JH; Punt CJ
    Eur J Cancer; 2009 Jul; 45(11):1935-49. PubMed ID: 19473832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
    Folprecht G; Köhne CH
    Nat Clin Pract Oncol; 2005 Nov; 2(11):578-87. PubMed ID: 16270098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer.
    Yu X; Li Z; Yu J; Chan MT; Wu WK
    Cell Prolif; 2015 Oct; 48(5):503-10. PubMed ID: 26202377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer.
    Jensen NF; Smith DH; Nygård SB; Rømer MU; Nielsen KV; Brünner N
    Scand J Gastroenterol; 2012 Mar; 47(3):340-55. PubMed ID: 22181013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer.
    Bhushan S; McLeod H; Walko CM
    Clin Colorectal Cancer; 2009 Jan; 8(1):15-21. PubMed ID: 19203892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.
    Khayat D; Gil-Delgado M; Antoine EC; Nizri D; Bastian G
    Oncology (Williston Park); 2001 Apr; 15(4):415-29; discussion 429-30, 433-4. PubMed ID: 11346931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.
    Kline CL; Schiccitano A; Zhu J; Beachler C; Sheikh H; Harvey HA; Mackley HB; McKenna K; Staveley-O'Carroll K; Poritz L; Messaris E; Stewart D; Sivik J; El-Deiry WS
    Clin Colorectal Cancer; 2014 Jun; 13(2):119-26. PubMed ID: 24461492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer.
    Grem JL
    Semin Oncol; 2005 Feb; 32(1):120-7. PubMed ID: 15726514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Systemic treatment of colorectal cancers--factual standards and perspectives].
    Miron L
    Rev Med Chir Soc Med Nat Iasi; 2003; 107(4):752-8. PubMed ID: 14756014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.
    Dy GK; Krook JE; Green EM; Sargent DJ; Delaunoit T; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pockaj BA; Sticca RP; Alberts SR; Pitot HC; Goldberg RM;
    J Clin Oncol; 2007 Aug; 25(23):3469-74. PubMed ID: 17687151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive markers for colorectal cancer: current status and future prospects.
    Longley DB; McDermott U; Johnston PG
    Clin Colorectal Cancer; 2003 Feb; 2(4):223-30. PubMed ID: 12620141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of new agents in the treatment of colorectal cancer.
    Folprecht G; Köhne CH
    Oncology; 2004; 66(1):1-17. PubMed ID: 15031593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.
    Delaunoit T; Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Findlay BP; Thomas SP; Salim M; Schaefer PL; Stella PJ; Green E; Mailliard JA
    Cancer; 2004 Nov; 101(10):2170-6. PubMed ID: 15470715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant therapy for colon cancer 2005: new options in the twenty-first century.
    Leichman CG
    Surg Oncol Clin N Am; 2006 Jan; 15(1):159-73. PubMed ID: 16389156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent results of irinotecan therapy in colorectal cancer].
    Láng I; Hitre E
    Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line therapy in colorectal cancer.
    Berlin J
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 11):21-6. PubMed ID: 11204658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions.
    Schmoll HJ
    Semin Oncol; 2002 Oct; 29(5 Suppl 15):34-9. PubMed ID: 12422306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.